Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Precision Biosciences (DTIL) EBT Margin (2018 - 2025)

Precision Biosciences (DTIL) has disclosed EBT Margin for 8 consecutive years, with 153861.54% as the latest value for Q3 2025.

  • On a quarterly basis, EBT Margin fell 15042959.0% to 153861.54% in Q3 2025 year-over-year; TTM through Sep 2025 was 12322.06%, a 1230731.0% decrease, with the full-year FY2024 number at 30.83%, up 4773.0% from a year prior.
  • EBT Margin was 153861.54% for Q3 2025 at Precision Biosciences, down from 117327.78% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 179.47% in Q4 2022 to a low of 153861.54% in Q3 2025.
  • A 5-year average of 18624.03% and a median of 188.9% in 2022 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: surged 306496bps in 2021, then plummeted -15042959bps in 2025.
  • Precision Biosciences' EBT Margin stood at 484.52% in 2021, then surged by 137bps to 179.47% in 2022, then crashed by -208bps to 193.83% in 2023, then crashed by -1820bps to 3721.63% in 2024, then plummeted by -4034bps to 153861.54% in 2025.
  • Per Business Quant, the three most recent readings for DTIL's EBT Margin are 153861.54% (Q3 2025), 117327.78% (Q2 2025), and 72906.9% (Q1 2025).